The global clinical laboratory services market size was estimated at USD 233.63 billion in 2024 and is projected to grow at a CAGR of 3.82% from 2025 to 2030. The market is witnessing growth due to factors such as the increasing burden of chronic diseases and the growing demand for early diagnostic tests. Moreover, rapid advancements in data management and sample preparation due to growing volumes of testing samples are anticipated to boost market growth during the forecast period.
Clinical lab services are widely used for various applications, primarily for detecting and quantifying different biological substances. Variations in biomolecular concentrations can indicate various abnormal metabolic activities, infections, infectious and non-infectious diseases, and inflammatory conditions. To ensure optimal clinical results and overall public health, it's vital to rapidly and accurately diagnose severe illnesses and administer appropriate treatment.
Automation in clinical settings has significantly improved the data management process in laboratories. Growing adoption of laboratory automation systems is expected to boost the market during the forecast period. Furthermore, database management tools, patient test records, and integrated workflow management systems have received significant consideration in the healthcare industry. This can be attributed mainly to companies that process nearly 100 to 150 billion samples per year. Hence, the improvement and implementation of informatics and automated data management solutions to perform seamless operations are anticipated to drive the market.
An increase in disease prevalence and high demand for early disease diagnosis are expected to boost the market in the coming years. These factors have prompted market players to introduce innovative services to address the growing demand. The introduction of accurate and technologically advanced products, such as companion diagnostics, biochips, & microarrays, has increased the demand for early disease detection. Products such as companion diagnostics also reduce the overall healthcare cost by helping physicians identify the most suitable treatment option based on a patient's genetic makeup.Furthermore, the growing prevalence of target diseases, such as cardiovascular diseases and diabetes, is a high-impact market driver over the forecast period. Cardiovascular disease has become the most dominant cause of mortality and morbidity in the world over the past three decades. According to the WHO, by 2030, cardiovascular diseases are estimated to cause approximately 23.6 million deaths, mainly due to heart disease and stroke. Moreover, the global prevalence of diabetes is constantly increasing, creating a large patient pool for the clinical laboratory services industry.
The clinical laboratory services industry demonstrates a high degree of innovation, driven by a moderate degree of innovation. This can be attributed to the advanced technologies and methodologies for transforming diagnostic practices. From novel testing approaches to automation, the sector continually evolves, enhancing accuracy and efficiency in healthcare diagnostics. For instance, in January 2023, QIAGEN released EZ2 Connect MDx, an in vitro diagnostics platform for automated sample processing for diagnostic laboratories. The device allows labs to purify RNA and DNA samples in 30 minutes.
The clinical laboratory services industry witnesses notable M&A activities by the leading players. Leading players are strategically joining forces toexpand and enhance their services, gain access to new technologies, consolidate in the rapidly growing market, and address the increasing strategic importance of clinical laboratory services. In February 2022, Laboratory Corporation of America Holdings acquired Personal Genome Diagnostics Inc. to expand its portfolio of oncology based NGS services.
The clinical laboratory services industry is highly regulated. The regulations ensure ensure safety standards, quality control, and fair competition. Countries have designated regulatory bodies that regulate the clinical laboratory services.In the United States, the application and safety aspects of laboratory tests and services are regulated and reviewed by the federal government through the Clinical Laboratory Improvement Amendments (CLIA). In addition to CLIA, the U.S. FDA is also involved in the regulations for clinical laboratory services industry.
The clinical laboratory services industry is undergoing significant transformation with the continuous expansion of service offerings to meet the growing and evolving needs of modern healthcare. This expansion is being driven by several key factors, including the rising global disease burden, increased demand for precision diagnostics, and advancements in medical technology. Laboratories are broadening their scope beyond traditional routine tests to include specialized services such as genetic and molecular diagnostics, companion diagnostics, pharmacogenomics, and next-generation sequencing (NGS). These services play a crucial role in the early detection and personalized treatment of complex diseases like cancer, neurological disorders, and infectious diseases
The clinical laboratory service industry is witnessing a growing number of geographical expansion strategies, with key players such as Quest Diagnostics and LabCorp employing this approach to broaden their service reach. This strategy enhances service availability across diverse geographic areas, ensuring a more extensive market presence.
The clinical laboratory services landscape is transforming strategically, fueled by emerging service opportunities that align with technological advancements and evolving patient needs. Key growth areas include liquid biopsy services, which are revolutionizing cancer diagnostics through minimally invasive testing, and at-home testing kits that offer convenience and accessibility for chronic disease monitoring and preventive care. Digital pathology is enhancing diagnostic accuracy and speed by enabling remote slide analysis and AI integration, while machine learning technologies are streamlining operations and delivering predictive insights across lab workflows.
Based on test type, the clinical chemistry segment led the market with the largest revenue share of 56.60% in 2024. The segment's dominance is attributed to numerous clinical chemistry tests involved in the pathology analysis of body fluids, including analysis of urine, plasma, serum, and other body fluids. Clinical chemistry or biochemistry tests are integral to basic-level diagnosis and laboratory testing. Some of the common tests for clinical chemistry include glucose, creatinine, urea, total protein, globulins, albumin, bilirubin, alanine transaminase (ALT), aspartate transaminase (AST), alkaline phosphatase (ALP), andgamma-glutamyl transpeptidase (GGT), among others. Techniques such as spectrophotometry, immunoassay, and electrophoresis are used to measure the concentration of different types of molecules present in the collected sample. Increasing automation to enhance customer experience is gaining traction in the segment.
The genetics testing segment is projected to show at a lucrative CAGR during the forecast period. This can be attributed to an increase in intensive research activities on genetic and proteomic studies, in the context of hereditary & gene-mutation-related disorders. Moreover, there is an increasing demand for personalized care, with accurate and early diagnosis in oncology expected to fuel segment growth. The rising need for efficient tests in the early diagnosis of major infections and cancer is anticipated to boost the segment's growth.
Based on service provider, the hospital-based laboratories segment accounted for the largest market share in 2024. This dominance is attributive to the high turnaround number of patients’ tests, mainly for complex and severe disease conditions that are comparatively more cost-intensive. It is expected to maintain its dominance owing to the increasing number of hospitals integrating laboratories into their premises. The expansion of outreach programs initiated by hospitals, along with the quick turnaround of patients grappling with severe and major diseases, is projected to propel the segment's growth. For instance, in February 2023, Tenaris, along with San Jose Municipal Hospital in Campana, launched a new laboratory in Argentina to improve the capability of testing in the country.
The stand-alone laboratories segment is expected to show at a lucrative CAGR over the forecast period. The market growth is owing to efforts to improve patient outcomes by providing diagnostic facilities at the retail level. Moreover, the ability of standalone labs to handle large volumes of diagnostic tests at an expedited rate and provide better results at comparatively lower prices is anticipated to offer economies of scale to service providers. There has been an increasing growth of the standalone market since the outbreak of the COVID-19 pandemic. In addition, emerging players providing standalone clinical lab testing services are expected to make a significant contribution to the segment’s rapid growth.
Based on application, the bioanalytical & lab chemistry services segment accounted for the largest revenue share in 2024. Bioanalytical & lab chemistry laboratories use a wide range of techniques and technology platforms to fulfill diagnostic needs. ELISA, chromatography, immunochemistry, mass spectroscopy, and molecular biology are the most commonly used technologies in bioanalytical & lab chemistry applications. Bioanalytical services are an essential tool in drug discovery and development for determining the concentration of drugs and their metabolites. For instance, in November 2021, Labcorp launched a bioanalytical laboratory in Singapore, expanding its bioanalytical presence in Asia Pacific.
The toxicology testing services segment is expected to register at a lucrative CAGR during the forecast period. Toxicology testing services include the identification of chemicals, drugs, and other toxic elements that affect patients and help clinicians in predicting future toxic effects, confirming a different diagnosis, or guiding therapy. Moreover, market players are adopting various strategies, including mergers and acquisitions, contributing to segment growth. For instance, in January 2023, Aegis Sciences Corporation acquired HealthTrackRx's Toxicology business unit, strengthening Aegis's toxicology portfolio. This allows Aegis to provide comprehensive clinical toxicology testing, while HealthTrackRx concentrates on expanding its capabilities in PCR infectious disease testing. Similarly, in August 2022, LifeNet Health LifeSciences launched a human-relevant cell-based assay service by the acquisition of IONTOX, aiding in cytotoxic screening, biocompatibility assay, and a next-generation multi-organ platform. The main services in toxicity testing include urine testing, hair testing, blood testing, and saliva testing.
North America dominated the clinical laboratory services market with the largest revenue share of 37.24% in 2024. Major factors contributing to the largest share include high prevalence of chronic diseases, well-established healthcare infrastructure, and a rising geriatric population. The region shows the presence of a well-established healthcare system and reimbursement framework for clinical laboratory services. Moreover, new players are entering the market owing to the lucrative nature of the business in the country. For instance, in February 2023, Dutch biotech company Detact Diagnostics announced setting up a new laboratory in Keene State College (U.S.) with a 2-year rental contract. Moreover, leading clinical laboratories that offer patients and healthcare professionals crucial diagnostic information are represented by the American Clinical Laboratory, a national trade group.
The clinical laboratory services market in the U.S. is rapidly growing, driven by the FDA has proposed regulations to oversee laboratory-developed tests (LDTs), aiming to ensure their safety and effectiveness. This regulatory shift presents both challenges and opportunities for laboratories to enhance test reliability and foster innovation. The integration of digital health solutions and personalized medicine further offers avenues for growth, enabling more precise and efficient patient care.
The clinical laboratory services market in Europe is rapidly evolving, driven by the region's benefits from significant investments in research and development, leading to advancements in diagnostic technologies such as chemiluminescence immunoassays and real-time PCR. For instance, the UK government allocated USD 2 billion to establish over 155 Community Diagnostic Centers, delivering more than 7 million tests by March 2023. These initiatives enhance early disease detection and streamline patient pathways. Opportunities lie in the continued adoption of high-throughput assays and the expansion of personalized medicine approaches. However, the market faces challenges, including the need for standardized regulations across countries and addressing disparities in access to advanced diagnostic services.
The UK clinical laboratory services market is experiencing significant growth. The establishment of Community Diagnostic Centers has expanded access to testing, reducing waiting times and improving patient outcomes. The NHS's commitment to integrating advanced technologies, such as mass spectrometry and flow cytometry, enhances diagnostic accuracy and efficiency. In addition, collaborations between the public and private sectors are fostering innovation in laboratory services. Opportunities exist in the expansion of personalized medicine, requiring sophisticated diagnostic capabilities. The market also benefits from a skilled workforce and a strong regulatory framework. However, challenges include managing the increasing demand for services and ensuring equitable access across regions.
The clinical laboratory services market in Germany is growing rapidly, supported by a robust healthcare system and a focus on technological innovation. German healthcare providers are increasingly adopting automated and high-throughput testing solutions to enhance efficiency and accuracy. Major players are forming partnerships to introduce new lab testing services, expanding their offerings and market reach. The country's emphasis on quality standards and regulatory compliance ensures reliable diagnostic outcomes. Opportunities abound in the integration of digital health tools and the expansion of molecular diagnostics. However, the market must navigate challenges such as workforce shortages and the need for continuous investment in infrastructure and training.
The clinical laboratory services market in the Asia Pacific region is expected to grow at the fastest CAGR of 5.30% over the forecast period. The growth of the region is largelydue to escalating scientific research, unmet medical needs, economic growth, and improvements in healthcare infrastructure and regulations. Increasing public awareness and the availability of advanced medical treatments are anticipated to bolster the region's growth. Clinical laboratory services have gained significant importance during the COVID-19 pandemic due to heightened demand for testing. Major players are focusing on partnerships to introduce new lab testing services.
The China clinical laboratory services market is expanding rapidly, driven by healthcare reforms, a large and aging population, and increased government investments in diagnostics. The rising prevalence of chronic diseases and urbanization contributes to the growing demand for laboratory services. Technological advancements, including the adoption of next-generation sequencing and automation, are enhancing diagnostic capabilities. Opportunities exist in the development of personalized medicine and the integration of artificial intelligence in diagnostics.
The clinical laboratory services market in Japan is expanding rapidly, driven by an aging population and a focus on early disease detection. The country's healthcare system emphasizes preventive care, increasing the demand for diagnostic testing. Technological innovations, such as advanced imaging and molecular diagnostics, are being integrated into laboratory services. Opportunities lie in the expansion of personalized medicine and the use of digital health solutions to streamline processes. Challenges include addressing workforce shortages and ensuring the sustainability of healthcare funding amidst demographic changes.
The clinical laboratory services market in Latin America is driven by the rising burden of chronic diseases and the adoption of advanced diagnostic technologies. Laboratories are investing in digitalization initiatives, such as laboratory information management systems (LIMS) and electronic health records (EHRs), to streamline processes. Opportunities exist in the integration of telemedicine platforms, enhancing access to diagnostic services. However, the market faces challenges like unclear regulatory frameworks and the need for workforce development.
The Brazil clinical laboratory services market is witnessing substantial growth. The market is witnessing substantial growth, supported by increased private investment and government reforms. The implementation of an electronic submission system for ethical approvals accelerates the process of test assessment and clinical trials. Opportunities lie in the expansion of genetic testing services and collaborations with international partners. Challenges include addressing ethical concerns and improving infrastructure in underserved regions.
The clinical laboratory services market in Middle East and Africa (MEA) is poised for growth driven by driven by the increasing prevalence of chronic diseases, advancements in diagnostic technology, and rising healthcare expenditure. The region is witnessing substantial investments in healthcare infrastructure, enhancing access to quality diagnostic services. Opportunities exist in the adoption of personalized medicine and the expansion into emerging markets with untapped potential. However, challenges such as limited accessibility in remote areas and cost constraints for advanced tests need to be addressed to ensure equitable healthcare delivery.
The Saudi Arabia clinical laboratory services market is experiencing steady growth, supported by government-led healthcare initiatives and the expansion of hospital infrastructure. The launch of the Seha Virtual Hospital, the largest virtual hospital globally, exemplifies the country's commitment to integrating digital health solutions. This initiative connects 224 hospitals and offers 44 specialized services, enhancing access to diagnostic care. Opportunities lie in the adoption of artificial intelligence and the development of personalized medicine. Challenges include ensuring the sustainability of healthcare funding and addressing workforce training needs to support the evolving landscape.
Some of the key players operating in the clinical laboratory services industry are Laboratory Corporation of America Holdings, Quest Diagnostics Incorporated, QIAGEN NV, Eurofins Scientific SE, Siemens Medical Solutions USA, Inc., and NeoGenomics Laboratories. These key players adopt various strategies to compete with their peers and drive growth. Companies are involved in expanding their market presence by entering into partnerships, collaborations, and agreements with other players to expand their product portfolio and geographic reach.
OPKO Health, Inc., ARUP Laboratories,and Sonic Healthcare are some of the emerging market participants in the clinical laboratory services industry. Emerging companies are employing various strategies to expand their footprint and grow at a fast pace. Customer acquisition strategies are being adopted by partnering with hospitals and clinics.
The following are the leading companies in the clinical laboratory services market. These companies collectively hold the largest market share and dictate industry trends.
In August 2023, Laboratory Corporation of America Holdings entered into an agreement with Tufts Medicine. Under the agreement, Labcorp will acquire Tufts Medicine Outreach Laboratory Business to expand its diagnostic testing and laboratory services.
In July 2023, DiaCarta, Ltd. partnered with Hopkins MedTech Lab Services and Hopkins MedTech Compliance to support the development and validation of laboratory-developed tests in the U.S.
In February 2023, Dutch biotech company Detact Diagnostics announced setting up a new laboratory in Keene State College (U.S.) with a 2-year rental contract.
Report Attribute |
Details |
Market size value in 2025 |
USD 237.76 billion |
Revenue forecast in 2030 |
USD 286.77 billion |
Growth rate |
CAGR of 3.82% from 2025 to 2030 |
Base year for estimation |
2024 |
Historical data |
2018 - 2023 |
Forecast period |
2025 - 2030 |
Quantitative units |
Revenue in USD million/billion and CAGR from 2025 to 2030 |
Report coverage |
Revenue forecast, company ranking, competitive landscape, growth factors, and trends |
Segments covered |
Test type, application, service provider, region |
Regional scope |
North America; Europe; Asia Pacific; Latin America; MEA |
Country scope |
U.S.; Canada; Mexico Germany; UK; France; Italy; Spain; Denmark; Sweden; Norway; China; Japan; India; Australia; South Korea; Brazil; Mexico; Colombia; Peru; Argentina; South Africa; Saudi Arabia; UAE; |
Key companies profiled |
Laboratory Corporation of America Holdings (LabCorp); QIAGEN; Eurofins Scientific; Quest Diagnostics Incorporated; OPKO Health, Inc.; Siemens Healthineers AG; NeoGenomics Laboratories; Fresenius Medical Care; ARUP Laboratories; Sonic Healthcare Limited; Charles River Laboratories; SYNLAB International; Mayo Clinic Laboratories; Unilabs |
Customization scope |
Free report customization (equivalent up to 8 analyst’s working days) with purchase. Addition or alteration to country, regional & segment scope. |
Pricing and purchase options |
Avail customized purchase options to meet exact research needs. Explore purchase options |
This report forecasts revenue growth and provides an analysis on the latest trends in each of the sub-segments from 2018 to 2030. For this report, Grand View Research has segmented the global clinical laboratory services market report on thetest type,application, service provider, and region:
Test Type Outlook (Revenue, USD Million, 2018 - 2030)
Genetic Testing
Clinical Chemistry
Routine Chemistry Testing
Therapeutic Drug Monitoring Testing
Endocrinology Chemistry Testing
Specialized Chemistry Testing
Other Clinical Chemistry Testing
Medical Microbiology Testing
Infectious Disease Testing
Transplant Diagnostic Testing
Other Microbiology Testing
Hematology Testing
Immunology Testing
Cytology Testing
Drug of Abuse Testing
Other Esoteric Tests
Service Provider Outlook (Revenue, USD Million, 2018 - 2030)
Hospital-Based Laboratories
Stand-Alone Laboratories
Clinic-Based Laboratories
Application Outlook (Revenue, USD Million, 2018 - 2030)
Bioanalytical & Lab Chemistry Services
Toxicology Testing Services
Cell & Gene Therapy Related Services
Preclinical & Clinical Trial Related Services
Drug Discovery & Development Related Services
Other Clinical Laboratory Services
Regional Outlook (Revenue, USD Billion, 2018 - 2030)
North America
U.S.
Canada
Mexico
Europe
UK
Germany
France
Italy
Spain
Denmark
Sweden
Norway
Asia Pacific
Japan
China
India
Australia
South Korea
Thailand
Latin America
Brazil
Colombia
Peru
Argentina
Middle East and Africa
South Africa
Saudi Arabia
UAE
Kuwait
b. The global clinical laboratory services market size was estimated at USD 233.63 billion in 2024 and is expected to reach USD 237.76 billion in 2025.
b. The global clinical laboratory service market is expected to grow at a compound annual growth rate of 3.82% from 2025 to 2030 to reach USD 286.77 billion by 2030.
b. Clinical chemistry dominated the clinical laboratory service market with a share of 54.44% in 2024 owing to the wide usage of tests related to urine, plasma, serum, and other body fluids for disease screening.
b. Some of the key service providers in the market include QIAGEN, ARUP Laboratories., Quest Diagnostics Incorporated, OPKO Health, Inc., Abbott, Siemens Medical Solutions USA, Inc., NeoGenomics Laboratories., Fresenius Medical Care., Sonic Healthcare., Laboratory Corporation of America Holdings (LabCorp).
b. Key factors that are driving the clinical laboratory service market growth include the increasing burden of chronic disease prevalence coupled with consequent demand for the early diagnostic tests and rapid advances in data management & sample preparation due to growing volumes of testing samples.
b. North America led the clinical laboratory service market for clinical laboratory services and accounted for the largest revenue share of 37.12% in 2024, owing to the high burden of chronic diseases in the region.
NEED A CUSTOM REPORT?
We offer custom report options, including stand-alone sections and country-level data. Special pricing is available for start-ups and universities.
Request CustomizationWe are GDPR and CCPA compliant! Your transaction & personal information is safe and secure. For more details, please read our privacy policy.
"The quality of research they have done for us has been excellent."